Tag: Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity

  • CP2

    Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity

    A cell-permeable tricyclic pyranopyrone synthesized at Kansas State University as an anti-amyloidogenic agent, subsequently characterized as a mild inhibitor of mitochondrial complex I that activates AMPK-dependent neuroprotective signaling, crosses the blood-brain barrier, and reduces amyloid-beta, phosphorylated tau, oxidative stress, and neuroinflammation in multiple transgenic mouse models of familial Alzheimer’s disease.

    Abstract

    CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3′ nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer’s disease to Huntington’s disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer’s disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.